This is the hover veil
Menu
Menu
Home
Living
guidelines
Clinical
flowcharts
Topics
under review
Do you have a clinical question?
About the taskforce
About the guidelines
FAQs
News
Contact us
About the taskforce
About the guidelines
FAQs
News
Contact us
News
News
Communique
Video
Explainer
Media release
Topics
Aboriginal and Torres Strait Islander people
ACEIs/ARBs
ACEM
ACIPC
ACNN
Acute & Critical Care
Adult disease-modifying treatment flowchart
Adults
AHPA
ALEC
Allied Health Professions Australia
Anakinra
Angiotensin 2 receptor agonist (C21)
Antenatal corticosteroids
Anticoagulants
Anticoagulation
Antivirals
ANZ Guidelines
ANZICS
ANZJOG
ANZPID COVID-19 Clinical Reference Group
Aprepitant
ARC
ASCOT
Asha Bowen
ASID
ATAGI
Australasian Sleep Association
Australia Day honours
Australian and New Zealand Society for Geriatric Medicine
Australian College of Midwives
Australian Commission on Safety and Quality in Health Care
Australian Living Evidence Consortium
Azithromycin
Baloxavir marboxil
Bamlanivimab
Bamlanivimab plus etesevimab
barac
Baricitinib
Basic Life Support
Bebtelovimab
BESSI principles
Breastfeeding
Brendan McMullan
Bridget Barber
Bromhexine hydrochloride
Budesonide
Budesonide for children and adolescents
Burnet
Camostat mesilate
Canakinumab
Cardiac arrest
Cardiac Arrest Working Group
Care of Children
Carol Hodgson
Casirivimab plus imdevimab
Casirivimab plus imdevimab (REGEN-COV)
Casirivimab plus imdevimab in children and adolescents
CD24c
CENA
Chemophrophylaxis
Chemoprophylaxis Panel
CHF
Children & adolescents
Children and adolescents
Chloroquine
Ciclesonide
Clinical flowcharts
CMCS
Cochrane
Cochrane Convenes
Cochrane Reviews
Colchicine
COMET-ICE
Consumer Panel
Convalescent plasma
Corticosteroids
COVID-19 COS
CPAP/HFNO
CPR
CPR Flowcharts
Critical Disease Panel
Croup
CT-P59 monoclonal antibody
Darunavir-cobicistat
Decision aid
Decision Tool
Delayed umbilical cord clamping
Dexamethasone
Disease-modifying treatments
Disease-Modifying Treatments Panel
DMT flowchart for children and adolescents
DMTC Panel
Drug treatments
Dutasteride
ECMO
Enisamium
Evusheld
Expert Advisory Group
Extracorporeal membrane oxygenation
Eye protection
Face masks
Facebook
Favipiravir
Flowchart
GIN
Global Commission on Evidence
GPs
Guideline Leadership Group
Guidelines Leadership Group
HCW
High-flow nasal oxygen
Hospital and Acute Care Panel
Hydroxchloroquine
Hydroxychloroquine
Hydroxychloroquine plus azithromycin
Ian Potter Foundation
ICEG
Imatinib
Immunodulatory treatments table
Immunoglobulin
Immunoglobulin plus methylprednisolone
Immunosuppressed
Infection Control Matters Podcast
Infection Prevention and Control (IPC) Panel
Infectious Disease
Inhaled corticosteroids
Interferon beta-1a
Interferon Gamma
Interferon β-1a (inhaled)
International Women's Day
Intravenous immunoglobulin
IPC
IPC Panel
Ivermectin
Josh Davis
Kawasaki Disease
Lancet
Leadership
Lenzilumab
Living Evidence
Long COVID
Lopinavir-ritonavir
Magnesium Sulfate
Management of cardiac arrest
Mild COVID-19
MJA
Molnupiravir
Molnupiravir (Lagverio)
Monoclonal antibody therapy
Murray PHN
N-acetylcysteine
NCIRS
Neonatal
Neonates
New England Journal of Medicine
New Topics & Questions
NHMRC
NICE
Nirmatrelvir plus ritonavir (Paxlovid)
Non-invasive ventilation
NPS MedicineWise
Observational Data Working Group
Oestrogen containing therapies
Oral antivirals
P2/N95 respirators
Paediatric
Paediatric & Adolescent Care
Paediatric & Adolescent Care Panel
Paediatric Care
Palliative and Aged Care Panel
Palliative Care
Palliative Care Working Group
Pathways to Care
Peginterferon lambda
Personal Protective Equipment (PPE)
PIMS-TS
Podcast
Post-acute COVID-19
Post-acute flowchart
post-exposure prophylaxis
Post-viral symptoms
Postnatal
PPE
pre-exposure prophylaxis
Pregnancy and breastfeeding women
Pregnancy and perinatal care
Pregnancy and Perinatal Panel
Pregnancy disease-modifying treatments flowchart
Pregnant & Breastfeeding Women
Pregnant & Postpartum women
Pregnant or breastfeeding women
Pregnant women
Primary and Chronic Care Panel
Prone positioning
Prone positioning for adults (non-ventilated)
Proxalutimide
Pulse oximeters
RANZCOG
RCTs
RECOVERY Trial
Regeneron
REGN-COV2
REMAP-CAP
Remdesivir
Respiratory
Respiratory management
Respiratory support
Risk classification tool
RMSANZ
Ronapreve
Royal Australian College of Surgeons
Ruxolitinib
Sarilumab
Senior Clinical Fellow
severe-critical COVID-19
SMS notifications
Sofosbuvir plus daclatasvir
Sotrovimab
Special populations
Steering Committee
Steroids
Steve McGloughlin
subcutaneous casirivimab plus imdevimab
Subscription
TaskforceTV
Telmisartan
TGA
THANZ
The Alfred
The Conversation
Thromboembolism
Timing of surgery
Tixagevimab plus cilgavimab (Evusheld)
Tocilizumab
Tociluzimab
Tofacitinib
Tracheostomy
Treatment
TSANZ
Umifenovir
Unvaccinated
Vaccination
Venous thromboembolism (VTE) prophylaxis
Videolaryngoscopy
Vitamin C
Vitamin D
VTE prophylaxis
Webinar
Zinc
Featured
COVID-19 Research Pipeline
STUDIES
Cochrane COVID-19 Study Register
137,915
Registered/ Published
RCT
s
covid-nma.com
4,281
Registered
658
Published
SYSTEMATIC REVIEWS
Prospero
6,015
Registered
As at 27 May 2022
Tweets by evidenceCOVID19
FILTERED BY > Azithromycin
Clear filter
Guidelines update, v41.2
22 July, 2021
Version 41.2 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of two new studies on disease-modifying treatments: Canakinumab NEW – one new study comparing canakinumab to placebo in 454 hospitalised patients with severe COVID-19 (Caricchio et al.) Azithromycin – one new study comparing azithromycin to placebo in 263 adult outpatients with COVID-19 (Oldenburg...
News
Guidelines update, v38.1
29 April, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include the following changes to the evidence summary sections for: - Lopinavir-ritonavir...
News
Guidelines update, version 34.1
18 February, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include: Dutasteride - preprint publication status has been removed from the summary information...
News
Communique #37
29 January, 2021
Following a well-earned break, the Taskforce team has now returned to full capacity. Global evidence surveillance continued throughout January, with six clinical panel meetings held since January 11....
Communique
Weekly Communique #24
24 September, 2020
WEEK IN REVIEW Six-month milestone for the Taskforce There was great anxiety among clinicians back in March, as Australia prepared to face the first wave of the COVID-19 pandemic and the...
Communique